Adenoid cystic carcinoma of the head and neck area is a rare malignant tumor with acceptable short-term but mediocre long-term prognosis. Radical tumor excision with clear resection margins, and sometimes resection of the facial nerve due to perineural growth, remains the fundamental therapy. We present 3 distinct clinical cases and discuss the current therapeutic options with special focus on plastic-reconstructive techniques. For reconstruction, the full armament of local and free flaps, as well as prosthetics, may be necessary. Adjuvant radiotherapy increases local control in advanced stages or close resection margins. However, systemic treatment options are limited. Further multicenter clinical trials are necessary due to the rare occurrence of the tumor.
Introduction
Adenoid cystic carcinoma of the head and neck area (ACCHN) is a rare malignant entity originating from the salivary glands. ACCHN mainly appears as a slowly but relentlessly growing painless mass. In contrast to squamous cell head and neck cancer, ACCHN exhibits early perineural growth patterns, with facial nerve paralysis and early hematogenous metastasis to the lungs. Lymph node metastases of the neck are less frequently found but may be present in up to 30%. 1, 2 If local tumor control can be achieved by radical surgery, 5-year overall survival is acceptable at 80 to 90%. 3 However, defect reconstruction can be challenging in advanced cases. Microvascular flaps and interposition nerve grafts need to be available, depending on the location of the primary tumor and the functional defects created by tumor resection.
Adjuvant radiotherapy is indicated in advanced tumor stages or after close margin resection. Treatment failure with the development of hematogenous lung metastases often limits long-term survival.
Reliable data on systemic therapeutic approaches are rare. Classic chemotherapeutic regimens (e.g., cisplatin or targeted therapies including blockade of epidermal growth factor receptor) rarely achieve stable disease or partial response for several months, and the majority of patients shows tumor progression with little benefit during systemic therapy. 4, 5 Here, we present the clinical course of 3 complex clinical cases of ACCHN from Ulm University Medical Center and discuss the current oncologic treatment and plastic-reconstructive options.
Case reports Patient 1. First, we report on a 57-year-old woman who initially suffered from slowly advancing visual impairment and a painless palpable mass above the left orbit. A computed tomography (CT) scan of the head revealed a suspicious mass of the lacrimal gland with infiltration of the orbital fat and erosion of the skull base ( figure 1, A) .
Biopsy confirmed the diagnosis of ACCHN. Neurosurgical tumor resection with protection of the eyeball via a frontolateral orbitotomy, duraplasty, and reconstruction with titanium mesh and bone cement were performed. Adjuvant radiotherapy with 50 Gy was administered as a result of close margin resection.
After 3 years, a local recurrence of the tumor was detected in the maxillary sinus and masseter muscle by routine CT (figure 1, B ). Again, radical tumor resection was performed using a sublabial approach. Simultaneously, a suspicious lesion of the lingula of the lung was found by positron emission tomography (PET)-CT, and an atypical lung resection confirmed the diagnosis of distant ACCHN metastases. Seven months later, a large recurrence of the tumor was discovered in the midface, producing an infraorbital hypoesthesia (figure 1, C). Pulmonary metastases were stable, and the patient was in good general condition.
The patient again underwent radical tumor resection with hemi-maxillectomy, orbital exenteration, and reconstruction of the midface with a microvascular radial forearm flap and an obturator plate (figure 1, D). After good wound healing, satisfying aesthetic and functional rehabilitation was achieved by a bone-anchored facial prosthesis and dental bridge (figure 1, E and F). The patient recovered well from surgery, and follow-up at 12-months showed no local recurrence or distant progression.
Patient 2.
A 64-year-old woman with painful swelling of the right parotid gland was diagnosed initially with sialadenitis and treated with antibiotics. Ultrasound examination showed no signs of tumor or pathologic lymph nodes. Several months later, the patient presented with a mild facial paralysis and atrophy of the left orbicularis oris muscle. A magnetic resonance image (MRI) was highly suspicious for a malignant parotid gland tumor. Gross needle biopsy was unable to confirm malignancy, probably because of the location of the tumor in the deep layer of the gland.
Total parotidectomy was performed, and pathologic examination of the fresh frozen sections confirmed the diagnosis of an ACCHN. Furthermore, the tumor was found to encase the main trunk of the facial nerve, close to the stylohyoid foramen. Therefore, resection of the main trunk with interposition of the great auricular nerve was included in the procedure, combined with a 1.2-g platinum inlay onto the tarsal plate of the upper eyelid (figure 2). Because of lymph node involvement, adjuvant radiotherapy was delivered. After follow-up at 2 years, facial mimics had mostly recovered, with a slight residual facial paralysis (House-Brackmann II) and, importantly, no evidence of disease.
Patient 3. The third patient was a 72-year-old woman who first noticed a painless lump in the left paranasal region. Incisional biopsy was performed, and histopathologic workup was not able to differentiate definitively between basal cell adenoma and carcinoma.
For further diagnosis, complete tumor resection was performed, and it showed an ACCHN with perineural growth and with microscopically positive margins. After completion of staging, radical resection of the tumor margins was performed, with no additional vital tumor tissue apparent on pathologic workup. Adjuvant radiotherapy with 60 Gy was delivered on account of the long course of surgical treatment, diffuse tissue invasion by the tumor, and perineural growth patterns.
After 15 months of uneventful clinical follow-up, a large regional tumor recurrence infiltrating the frontal and sphenoid sinus, the lamina cribrosa, the left orbit, and the middle cranial fossa was detected on MRI. Pa lliative systemic treatment consisting of 2 cycles of cisplatin, 5-fluoruracil, and cetuximab was administered. Imaging showed further tumor progression; therefore, 60 Gy proton beam radiation was added with partial response. Because of further tumor progression, the systemic regimen was changed to 4 cycles of cisplatin, doxorubicin, and cylclophosphamide, and later to monotherapy with vinorelbine. Further therapies with paclitaxel/ carboplatin and the tyrosine kinase inhibitor sunitinib as monotherapy showed little response.
In conclusion, whole body PET-C T s c a n showed disseminated disease with multiple organ and spine metastases. Regimens were stopped and the patient was changed to best supportive care. The patient passed away after several months.
Discussion
ACCHN is a rare malignant tumor with clinical and biological behavior that is different from that of squamous cell carcinoma of the head and neck area. The low incidence of approximately 0.25/100,000 complicates the implementation of large clinical trials and basic research. 6 The treatment of ACCHN seems compromised by several clinical features.
Patient 1's case illustrates the challenges of local tumor control and tissue reconstruction. In this patient, a negative margin after resection was achieved, but the eyeball was spared at the cost of a smaller safety margin. In the follow-up, the patient experienced several tumor recurrences and ultimately the loss of the eyeball and midfacial framework. This case shows that even if a histologically negative margin is achieved, the risk of locoregional recurrence remains high. Because of the low incidence of the disease, a systematic analysis of safe resection margins is hardly possible. Due to critical and vulnerable structures in the head and neck area (e.g., skull base or functionally relevant nerves and vessels), radical tumor resection must be discussed with the informed patient, analogous to malignant melanoma, in which 2-cm resection margins are intended in locally advanced disease.
Another challenge with patient 1 was the aesthetic and functional rehabilitation of the defect. For this purpose, the full arsenal of current reconstructive techniques may be necessary. A microvascular radial forearm flap was used to restore the tissue defect between the oral cavity and the midface, combined with an obturator plate and a dental bridge. The orbit and midface were additionally reconstructed with a bone-anchored Titanium-Epiplating System (Fa. Medicon; Tuttlingen, Germany) and a silicone facial and orbital prosthesis. 7 By this technique, an acceptable aesthetic and functional result was achieved ( figure 1) . Alternatively, a free scapula bone/fascia flap could be have been used for bony reconstruction with better options for dental rehabilitation. 8 As illustrated in the case of patient 2, the reconstruction of critical nerves is of major importance. Radical parotidectomy was performed for best oncologic outcome and safe margins. In this case, an immediate microsurgical nerve interposition of the great auricular nerve at the main trunk of the facial nerve was used. This technique is the gold standard and, if applicable, is superior to static facial rehabilitation in most cases. 9 The oncologic and functional outcomes were satisfying.
Facial nerve sacrifice is discussed in publications of large case series of ACCHN of the parotic gland. 10, 11 These authors found a benefit for local control and overall survival in patients with facial nerve sacrifice. This trend was statistically not significant, however, and patients suffered from decreased quality of life as a result of eating difficulties and aesthetic impairment. The authors suggest a facial nerve sacrifice, at least in cases of preoperative paralysis, and intraoperative encasement of the facial nerve. The benefits and risks of facial nerve sacrifice and reconstructive options must therefore be discussed with patients before the surgical treatment. Two more obstacles are illustrated in this case. In small tumor biopsies, the correct histopathologic diagnosis may be difficult to obtain, especially if the tumor biopsy includes the transition zone or border of tumor tissue to healthy tissue. 12 Consecutive diagnostic biopsies were required to secure the diagnosis of ACCHN. A definitive diagnosis must be available before radical tumor resection can be performed, which may lead to a diagnostic and therapeutic delay of several weeks and an increased risk for tumor cell spread during the diagnostic procedures. In our clinical database of 40 patients with ACCHN, approximately 10% were diagnosed with pleomorphic adenoma before the diagnosis was changed to ACCHN after definitive resection.
The final difficulty is the management of distant metastases. Patient 3's case especially illustrates the limited benefits of systemic therapies. Classical chemotherapies, as well as targeted therapeutic approaches, fail to show a significant impact on survival and tumor control. 2, 4, 5 Response rates are low, and only sometimes can stable disease be achieved; partial or complete remission is the exception. Due to the lack of randomized trials and control groups, the objective benefit of different therapeutic regimens can hardly be quantified. Clinical practice therefore remains an individual treatment regimen with platinum-based chemotherapy in combination with targeted therapy, depending on the general condition of the patient and the immunohistochemical profile of the tumor.
In conclusion, ACCHN represents a rare, highly aggressive tumor that presents challenges in terms of early and correct diagnosis, surgical resection, and reconstruction, as well as in the management of distant metastases. Multidisciplinary teams in high-volume centers, experienced in oncologic and reconstructive surgery, should take responsibility for patients with ACCHN.
